TY - JOUR T1 - P21-Driven Multifusion Gene System for Evaluating the Efficacy of Histone Deacetylase Inhibitors by In Vivo Molecular Imaging and for Transcription Targeting Therapy of Cancer Mediated by Histone Deacetylase Inhibitor JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 678 LP - 685 DO - 10.2967/jnumed.113.126573 VL - 55 IS - 4 AU - Ya-Ju Hsieh AU - Luen Hwu AU - Yi-Chieh Chen AU - Chien-Chih Ke AU - Fu-Du Chen AU - Hsin-Ell Wang AU - Kang-Ping Lin AU - Hsin-Hsien Yeh AU - Chi-Wei Chang AU - Ren-Shyan Liu Y1 - 2014/04/01 UR - http://jnm.snmjournals.org/content/55/4/678.abstract N2 - Overexpressed histone deacetylase (HDAC) activity has been linked with tumor initiation and progression that prompt the development of histone deacetylase inhibitors (HDACIs) as anticancer agents. HDACI was reported to be able to activate p21 promoter through the SP1 binding sites in the proximal region of p21WAF1/CIP1 promoter. In this study, we established a p21WAF1/CIP1 promoter–driven triple-fused reporter gene system (p21-3H) to evaluate the efficacy of HDACI and the ganciclovir (GCV)-mediated anticancer effect contributed by HDACI-induced and p21-driven truncated herpes simplex virus-1 thymidine kinase sr39 mutant (ttksr39) in vitro and in vivo. Methods: The p21-3H construct was generated and stably or transiently transfected into H1299 cell lines. These cells were treated with trichostatin A or vorinostat (suberoylanilide hydroxamic acid [SAHA]) to evaluate the activation of p21 promoter–driven reporter gene expression by in vitro confocal fluorescence microscopy, luciferase assay, 2′-fluoro-2′-deoxyarabinofuranosyl-5-ethyluracil (3H-FEAU) cellular uptake, in vivo bioluminescence imaging, and 9-(4-18F-fluoro-3-hydroxymethylbutyl) guanine (18F-FHBG) small-animal PET imaging. The therapeutic efficacy on p21-3H–expressing tumor xenografts was assessed by daily administration with SAHA (100 mg/kg intraperitoneally) or GCV (20 mg/kg) for 9 d, followed by tumor volume measurement. Results: On treatment with trichostatin A or SAHA, H1299 cells carrying p21-3H showed a significant increase of luciferase activity, cellular uptake of 3H-FEAU (Moravek), and DsRed expression. In vivo tumor xenografts carrying p21-3H also showed increased luciferase activity by luminescent imaging and enhanced accumulation of 18F-FHBG by small-animal PET imaging. Furthermore, when cells transfected with p21-3H or p21/PstI-3H (which lacks p53-binding sites) were treated, the increase of luciferase activity was similar in both groups, indicating that HDACI-induced p21 promoter activation is independent of p53. Both in vitro and in vivo results showed improved therapeutic effect by combined treatment of GCV and HDACI. Conclusion: We have established an HDACI-inducible, p21-driven reporter system that has the potential for evaluating the anticancer effect of HDACIs on cancer cells by multiple molecular imaging modalities. Furthermore, ttksr39 in a p21-3H reporter construct provides a potential combination with thymidine kinase–mediated gene therapy to optimize the therapeutic benefit of HDACI. ER -